AngioDynamics, Inc. (ANGO) Analysts See $0.17 EPS

September 16, 2018 - By Mark Mitchell

AngioDynamics, Inc. (NASDAQ:ANGO) LogoInvestors sentiment increased to 1.5 in 2018 Q2. Its up 0.04, from 1.46 in 2018Q1. It is positive, as 10 investors sold AngioDynamics, Inc. shares while 44 reduced holdings. 29 funds opened positions while 52 raised stakes. 35.30 million shares or 1.16% more from 34.89 million shares in 2018Q1 were reported.
Goldman Sachs Grp stated it has 0% of its portfolio in AngioDynamics, Inc. (NASDAQ:ANGO). Massachusetts Fin Svcs Ma accumulated 71,979 shares or 0% of the stock. The New York-based D E Shaw And Communication has invested 0.01% in AngioDynamics, Inc. (NASDAQ:ANGO). Peak6 Investments Limited Partnership owns 105 shares. Schwab Charles Incorporated, a California-based fund reported 286,197 shares. Segall Bryant Hamill Ltd Co has invested 0.26% in AngioDynamics, Inc. (NASDAQ:ANGO). Prudential owns 348,365 shares. Century Companies reported 238,555 shares. Fuller And Thaler Asset Mngmt, California-based fund reported 570 shares. Jpmorgan Chase & Company holds 0% or 769,223 shares in its portfolio. Eqis Capital Mngmt reported 20,020 shares. First Trust Advsr Limited Partnership, Illinois-based fund reported 41,709 shares. Tributary Capital Mngmt Limited Liability has 0.6% invested in AngioDynamics, Inc. (NASDAQ:ANGO). Cornercap Counsel Inc, a Georgia-based fund reported 44,895 shares. Moreover, Eam Invsts Limited Liability Corporation has 0.69% invested in AngioDynamics, Inc. (NASDAQ:ANGO).

Analysts expect AngioDynamics, Inc. (NASDAQ:ANGO) to report $0.17 EPS on September, 27.They anticipate $0.05 EPS change or 41.67 % from last quarter’s $0.12 EPS. ANGO’s profit would be $6.30 million giving it 34.97 P/E if the $0.17 EPS is correct. After having $0.20 EPS previously, AngioDynamics, Inc.’s analysts see -15.00 % EPS growth. The stock decreased 0.88% or $0.21 during the last trading session, reaching $23.78. About 212,645 shares traded. AngioDynamics, Inc. (NASDAQ:ANGO) has risen 30.51% since September 16, 2017 and is uptrending. It has outperformed by 14.89% the S&P500.

AngioDynamics, Inc. (NASDAQ:ANGO) Ratings Coverage

Among 2 analysts covering Angiodynamics (NASDAQ:ANGO), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Angiodynamics had 3 analyst reports since March 29, 2018 according to SRatingsIntel. The company was maintained on Monday, April 2 by Canaccord Genuity. The firm has “Hold” rating given on Thursday, March 29 by Canaccord Genuity. The stock of AngioDynamics, Inc. (NASDAQ:ANGO) earned “Outperform” rating by Raymond James on Tuesday, April 3.

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company has market cap of $881.65 million. The firm provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities. It has a 54.05 P/E ratio. It also offers AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

Another recent and important AngioDynamics, Inc. (NASDAQ:ANGO) news was published by which published an article titled: “AngioDynamics to acquire RadiaDyne” on September 13, 2018.

AngioDynamics, Inc. (NASDAQ:ANGO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.